Plant-derived vaccines represent a innovative approach to vaccine production, utilizing plants as bioreactors to produce antigens for immunization. This technology involves introducing genes encoding vaccine antigens into plant cells, prompting the plant to produce the desired proteins. Commonly used plants for this purpose include tobacco, potatoes, and tomatoes. The advantages of plant-derived vaccines include cost-effectiveness, scalability, and the potential to address storage and transportation challenges associated with traditional vaccine production. The plant-derived vaccine strategy has been explored for various infectious diseases, including hepatitis B, Norwalk virus, and influenza. The produced antigens can be extracted and purified for vaccine formulations. While plant-derived vaccines show promise, challenges such as regulatory approval, public acceptance, and optimizing expression levels persist. Nevertheless, ongoing research aims to refine this technology, explore novel plant hosts, and address the global demand for efficient and accessible vaccine production.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey